The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Micafungin is a relatively broad-spectrum antifungal agent available for clinical use in the US and Japan. By inhibiting the production of beta-1,3-glucan, an essential fungal cell wall component, micafungin has reduced toxicity to mammalian cells while maintaining potent antifungal activity against many pathogenic fungi including polyene- and azole-resistant isolates. Indeed, micafungin has been shown to be efficacious in the treatment of infections caused by Candida and Aspergillus species in clinical trials without the associated toxicities of amphotericin B formulations and drug interactions that occur with the azoles. In this review, the pharmacology, spectrum of activity, clinical efficacy and safety profile of micafungin are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 2×
“In the US, Candida species are the fourth most common organisms isolated from patients with nosocomial bloodstream infections [1].”
BackgroundEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Furthermore, invasive candidiasis is associated with substantial morbidity and mortality, with crude mortality rates approaching 40% [1,2].”
BackgroundComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 1×
“The response rates noted in the above studies are similar to those reported for anidulafungin (76%) and caspofungin (73%), as well as those of fluconazole and amphotericin B in clinical trials (Figure 2) [30,79-81].”
ResultWald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742 · cited 2×
“Similarly, the incidence of infections caused by Aspergillus species has increased three- to fourfold over the last two decades at major cancer centers [7-9].”
BackgroundKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Glucan Synthase Complex of Aspergillus fumigatus
Beauvais, A., Bruneau, J. M., Mol, P. C., Buitrago, M. J., Legrand, R., & Latgé, J. P. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.7.2273-2279.2001 · Cited by 209 · cited 1×
“In Aspergillus species the β-1,3-glucan synthase complex is located at the growing apical tips [22].”
Background
Cited by
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“Although they are active against the mycelial forms of dimorphic fungi, MICs are high for the yeast forms and this precludes their use for the treatment of infections caused by these fungi.([23,28,60]) Synergy between caspofungin and amphotericin B lipid complex has been demonstrated in mouse models of disseminated Rh…”
BackgroundPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“Low or trace levels of drug are found in the urine and cerebrospinal and vitreous fluids [141].”
BackgroundGarcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
“In recent years, a great deal has been learned about echinocandin pharmacokinetics, safety, spectrum, efficacy, and resistance (2, 4, 16, 17, 27, 35, 48, 50, 52).”
BackgroundEchinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
Metadata
- Authors
- Wiederhold, N. P., & Lewis, J. S.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2007-05-22
- Volume
- 8
- Issue
- 8
- Pages
- 1155-1166
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2128243354
- Cited by
- 59
- References
- 19
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. https://app.cochat.ai/papers/10.1517/14656566.8.8.1155
- The paper
- Wiederhold, N. P., & Lewis, J. S. (2007). The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.8.8.1155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.